Literature DB >> 16131442

Platelet inhibitor therapy for patients with cardiovascular disease: looking toward the future.

Wael A Aljaroudi1, Abdul R Halabi, Robert A Harrington.   

Abstract

Understanding platelet function and the role of platelets in the response to vascular injury has led to the development of novel platelet-inhibiting therapies that have been proven effective in the treatment of acute and chronic vascular disease. Antiplatelet therapies are cornerstone treatments for patients with acute coronary syndromes and have been essential in reducing the acute and subacute ischemic complications of percutaneous coronary intervention. Furthermore, an increased understanding of the pathobiology behind the platelet's role in atherothrombosis has offered up many new avenues of research and many new targets for therapeutic drug development. This review briefly summarizes the state of available anticoagulant and antiplatelet treatments in cardiovascular disease management and provides a perspective on the key issues in developing new antiplatelet strategies in the future.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16131442

Source DB:  PubMed          Journal:  Curr Hematol Rep        ISSN: 1540-3408


  4 in total

1.  High platelet count as a link between renal cachexia and cardiovascular mortality in end-stage renal disease patients.

Authors:  Miklos Z Molnar; Elani Streja; Csaba P Kovesdy; Matthew J Budoff; Allen R Nissenson; Mahesh Krishnan; Stefan D Anker; Keith C Norris; Gregg C Fonarow; Kamyar Kalantar-Zadeh
Journal:  Am J Clin Nutr       Date:  2011-08-03       Impact factor: 7.045

2.  The association between platelet indices and cardiovascular events in chronic kidney disease patients without dialysis.

Authors:  Zhikai Yu; Jiachuan Xiong; Ke Yang; Yinhui Huang; Ting He; Yanlin Yu; Jinghong Zhao
Journal:  Int Urol Nephrol       Date:  2021-01-02       Impact factor: 2.370

3.  Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis.

Authors:  Elani Streja; Csaba P Kovesdy; Sander Greenland; Joel D Kopple; Charles J McAllister; Allen R Nissenson; Kamyar Kalantar-Zadeh
Journal:  Am J Kidney Dis       Date:  2008-08-29       Impact factor: 8.860

Review 4.  Iron dosing in kidney disease: inconsistency of evidence and clinical practice.

Authors:  Adam E Gaweda; Yelena Z Ginzburg; Yossi Chait; Michael J Germain; George R Aronoff; Eliezer Rachmilewitz
Journal:  Nephrol Dial Transplant       Date:  2014-05-12       Impact factor: 5.992

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.